Samra Turajlic
#172,319
Most Influential Person Now
Medical oncologist and cancer researcher
Samra Turajlic's AcademicInfluence.com Rankings
Samra Turajlicphilosophy Degrees
Philosophy
#11370
World Rank
#15655
Historical Rank
Logic
#8186
World Rank
#10203
Historical Rank
Download Badge
Philosophy
Samra Turajlic's Degrees
- Doctorate Medicine Harvard University
- PhD Cancer Biology Johns Hopkins University
Why Is Samra Turajlic Influential?
(Suggest an Edit or Addition)According to Wikipedia, Samra Turajlic is a medical oncologist and cancer researcher. She leads the cancer dynamics lab at the Francis Crick Institute in London, which focuses on understanding how cancers evolve, as well as working as an oncologist at the Royal Marsden.
Samra Turajlic's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Tracking the Evolution of Non‐Small‐Cell Lung Cancer (2017) (1525)
- Phylogenetic ctDNA analysis depicts early stage lung cancer evolution (2017) (1092)
- Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution (2017) (772)
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. (2017) (597)
- Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal (2018) (514)
- Metastasis as an evolutionary process (2016) (444)
- Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal (2018) (391)
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies (2018) (376)
- Resolving genetic heterogeneity in cancer (2019) (349)
- Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal (2018) (333)
- SF3B1 mutations are associated with alternative splicing in uveal melanoma. (2013) (331)
- Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. (2013) (314)
- Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition (2021) (306)
- Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors (2017) (292)
- Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors (2017) (292)
- Whole genome sequencing of matched primary and metastatic acral melanomas. (2012) (161)
- Pervasive chromosomal instability and karyotype order in tumour evolution (2020) (160)
- Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma (2013) (153)
- Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. (2016) (125)
- BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling (2014) (119)
- Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. (2017) (113)
- Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study (2021) (97)
- The mutational burden of acral melanoma revealed by whole‐genome sequencing and comparative analysis (2014) (94)
- Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature (2016) (92)
- Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. (2018) (88)
- Kidney cancer: The next decade (2018) (84)
- COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety (2022) (73)
- Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma (2021) (68)
- The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. (2022) (66)
- SnapShot: Renal Cell Carcinoma (2015) (65)
- A whole‐genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor‐negative and ‐positive breast cancers (2012) (65)
- Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition (2014) (53)
- Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2 (2021) (52)
- Inferring mutational timing and reconstructing tumour evolutionary histories. (2015) (52)
- Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2 (2021) (52)
- Escape from nonsense-mediated decay associates with anti-tumor immunogenicity (2019) (51)
- Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer (2022) (46)
- Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm (2013) (45)
- Genomic characterisation of acral melanoma cell lines (2012) (43)
- Tracking Cancer Evolution through the Disease Course. (2021) (43)
- Predictive biomarkers for response to immune checkpoint inhibition. (2021) (40)
- Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. (2020) (37)
- An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors (2019) (36)
- Selection of metastasis competent subclones in the tumour interior (2020) (35)
- How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma? (2015) (33)
- Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study (2020) (33)
- Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer (2021) (32)
- Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series (2016) (27)
- Implications of cancer evolution for drug development (2017) (27)
- Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. (2021) (26)
- How we treat neurological toxicity from immune checkpoint inhibitors (2019) (26)
- Immunotherapy use outside clinical trial populations: never say never? (2021) (21)
- British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. (2020) (21)
- Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study (2021) (20)
- Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer (2021) (20)
- Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution (2017) (20)
- Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study (2021) (19)
- TRACERx Renal: tracking renal cancer evolution through therapy (2017) (19)
- The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. (2022) (19)
- Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. (2021) (18)
- First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma. (2018) (17)
- Tumour mutational burden: primary versus metastatic tissue creates systematic bias (2019) (16)
- Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma (2020) (16)
- SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay. (2021) (16)
- Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. (2021) (15)
- SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay (2020) (14)
- Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma (2018) (13)
- Phase I/II RAF kinase inhibitors in cancer therapy (2013) (12)
- Severe cutaneous adverse reaction following COVID‐19 vaccination and immunotherapy: a second hit? (2021) (11)
- The status of tumor mutational burden and immunotherapy (2022) (11)
- Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH (2020) (10)
- The GENIE Is Out of the Bottle: Landmark Cancer Genomics Dataset Released. (2017) (10)
- Evolution of Renal Cell Carcinoma (2020) (10)
- Generalized melanosis and melanuria in a patient with metastatic melanoma (2010) (10)
- 1557O Adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients: The CAPTURE study (2021) (10)
- WHO 2022 landscape of papillary and chromophobe renal cell carcinoma (2022) (9)
- An introduction to the WHO 5th edition 2022 classification of testicular tumours (2022) (9)
- Oligoprogression After Checkpoint Inhibition in Metastatic Melanoma Treated With Locoregional Therapy: A Single-center Retrospective Analysis (2020) (9)
- Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors (2021) (9)
- New survival standards for advanced melanoma (2020) (8)
- Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection (2018) (8)
- Immunity Report Fc-Optimized Anti-CD 25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors (2017) (8)
- Identification of Conserved Evolutionary Trajectories in Tumors (2020) (7)
- Immunotherapy for Melanoma Metastatic to the Brain. (2018) (7)
- Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer (2022) (7)
- Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab (2021) (7)
- Gastrointestinal cancer: Tracking tumour evolution through liquid biopsy (2015) (6)
- ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma. (2016) (6)
- PTU-009 Upper gastrointestinal inflammation in patients with immune-checkpoint inhibitor induced diarrhoea (2018) (5)
- Patterns of steroid use in diarrhoea and/or colitis (D/C) from immune checkpoint inhibitors (ICPI) (2016) (4)
- CAcTUS: A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma. (2021) (4)
- The Genetic Evolution of Metastasis. (2022) (4)
- The Biology of Tumour Evolution in Renal Cell Carcinoma. (2020) (4)
- Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. (2020) (4)
- Meta-analysis of tumor and T cell intrinsic mechanisms of sensitization to checkpoint inhibition (2020) (4)
- Cutaneous toxicities in patients with melanoma receiving checkpoint inhibitor therapy: a retrospective review. The experience of a single large specialist institution (2020) (4)
- PWE-025 Microscopic colonic inflammation in immune check point inhibitor-induced diarrhoea/colitis (2018) (4)
- Machine learning guided signal enrichment for ultrasensitive plasma tumor burden monitoring (2022) (4)
- Relapse models for clear cell renal carcinoma. (2015) (3)
- Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. (2022) (3)
- Antibodies against endogenous retroviruses promote lung cancer immunotherapy (2023) (3)
- Author Correction: Resolving genetic heterogeneity in cancer (2019) (3)
- PTU-005 Infliximab use in immune-related diarrhoea/colitis (IRD/C) (2018) (3)
- ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma (2019) (3)
- Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis (2022) (2)
- Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay (2022) (2)
- Current management of renal cell cancer (2017) (2)
- A protocol for representative sampling of solid tumors to improve the accuracy of sequencing results (2021) (2)
- Determinants of anti-PD1 response and resistance in clear cell renal cell carcinoma (2021) (2)
- Isolated imbalance due to bilateral vestibular failure following immune checkpoint inhibitor administration: two cases. (2021) (2)
- Systemic treatment of advanced papillary renal cell carcinoma: Where next? (2016) (2)
- 217 Identifying the metastatic subclone by exhaustive sampling of primary and metastasis in clear cell renal cell carcinoma (ccRCC) pair (2016) (2)
- What's new in WHO fifth edition – urinary tract (2022) (1)
- Abstract 3404: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. (2013) (1)
- Spatial patterns of tumour growth impact clonal diversification: computational modelling and evidence in the TRACERx Renal study (2021) (1)
- The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment (2022) (1)
- 543 Sensitive quantification and tracking of the active components of a Clonal Neoantigen T cell (cNeT) therapy: From manufacture to peripheral circulation (2021) (1)
- 880PBiomarkers before and after nephrectomy of locally advanced or metastatic renal cell carcinoma (RCC) treated with everolimus: Neorad phase 2 trial (PREDICT consortium) (2017) (1)
- Relatlimab and nivolumab in the treatment of melanoma (2022) (1)
- Academically led clinical trials: challenges and opportunities (2015) (1)
- With one eye on the future. (2022) (1)
- PTU-006 Incidence of immune check point inhibitor induced diarrhoea/colitis- experience from a multi-centre cohort (2018) (1)
- Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways. (2023) (1)
- Searching for the needle in the haystack: deconvoluting the evolutionary dynamics of residual disease in human glioblastoma (2019) (1)
- PWE-085 Immune checkpoint inhibitor induced acute liver injury – a national cohort study (2018) (1)
- CPC04: Immune checkpoint inhibitor therapy and psoriasis: a case series (2022) (1)
- 1136P Feasibility of linking the UK 100,000 genomes project and real-world evidence databases for a melanoma patient population (2020) (1)
- A phase II trial of nilotinib in the treatment of patients with KIT mutated advanced acral and mucosal melanoma (NICAM). (2011) (1)
- Predicting cancer evolution for patient benefit: Renal cell carcinoma paradigm. (2022) (1)
- Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases (2022) (1)
- Cytokine release syndrome in a patient with colorectal cancer following vaccination with BNT162b2 (tozinameran) (2021) (1)
- 9p21 Loss Defines the Evolutionary Patterns of Aggressive Renal Cell Carcinomas (2020) (1)
- Representative sequencing: Profiling extreme tumor diversity. (2018) (0)
- 193 The Achilles VELOSTM Process 2 boosts the dose of highly functional clonal neoantigen-reactive T cells for precision personalized cell therapies (2021) (0)
- Standing on the shoulders of giants (2019) (0)
- Abstract PR002: Advanced melanoma exhibits a diversity of evolutionary routes to lethality (2022) (0)
- 114 Clonal mTOR pathway activation as a predictive biomarker for mTOR inhibitor therapy in clear cell renal cell carcinoma (2016) (0)
- Cell-free DNA (c.f.D.N.A) recapitulates genomic profile of renal cell carcinoma (R.C.C) and corresponds to disease progression and therapy response (2018) (0)
- Representative sequencing: Profiling extreme tumor diversity. (2018) (0)
- 068 Immune checkpoint inhibitors: the neurologist’s role (2022) (0)
- FIRST RESULTS OF A‐PREDICT: A PHASE II STUDY OF AXITINIB IN PATIENTS WITH METASTATIC RENAL CELL CANCER (RCC) UNSUITABLE FOR NEPHRECTOMY: PNFLBA‐16 (2017) (0)
- SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay [version 1; peer review: 1 approved with reservations] (2021) (0)
- Abstract SY02-02: Understanding evolution of metastatic disease in renal cancer and melanoma (2021) (0)
- Abstract PO-091: CAPTURE: Cancer and COVID-19 antiviral immune monitoring study (2020) (0)
- Insights into PD-1 blockade : how the Fc region can modulate the therapeutic activity of monoclonal antibodies targeting PD-1 (2022) (0)
- Metastasis and organotropism: A look through the lens of large-scale clinical sequencing data. (2022) (0)
- Homogenisation of leftover surgical tissue across multiple cancer types: A feasibility study (HoLST-F) (2019) (0)
- Abstract A011: Detection of disseminated tumor cells in advanced clear cell renal cell carcinoma through research autopsy (2023) (0)
- Taking The Burden Out Of Symptom Reporting In Patients With Melanoma Using A Digital Real-World Evidence Platform (2018) (0)
- 58P Validation of the Achilles VELOS process 2 manufacturing platform for the treatment of solid cancer: GMP scale runs generate a significant dose boost of highly potent clonal neoantigen reactive T-cells (2021) (0)
- PS-025-Elevated tissue homing of monocytes and increased cytotoxic activity of CD8+ T-cells in immune checkpoint inhibitor-induced hepatitis (2019) (0)
- 197 Checkpoint inhibitor associated neuritis a novel pathological entity (2022) (0)
- Abstract CT054: The development of a personalized autologous clonal neoantigen T cell therapy for the treatment of solid cancer using the VELOSTMmanufacturing platform generates highly potent and reactive CD8+ and CD4+ T cells for clinical use (2020) (0)
- PCN206 PATIENT-REPORTED REAL-WORLD TREATMENT PATTERNS FOR MELANOMA IN THE UK MEASURED USING A DIGITAL 'BRING YOUR OWN DEVICE' PLATFORM (2019) (0)
- 208 Immune checkpoint inhibitor-related neurotoxicity: a case series (2019) (0)
- SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay [ version 2 ; peer review : 2 approved ] (2021) (0)
- WHO 2022 classification of penile and scrotal cancers: updates and evolution (2022) (0)
- 108 INFLIXIMAB TREATMENT FOR CHECKPOINT INHIBITOR INDUCED COLITIS: CLINICAL OUTCOMES FROM A MULTI-CENTRE STUDY (2021) (0)
- Abstract A012: Advanced melanoma exhibits a diversity of evolutionary routes to lethality (2022) (0)
- Pathogenesis, clinical evolution and outcomes of patients with immune checkpoint inhibitor induced acute liver injury: A multicentre study. (2018) (0)
- Abstract 875: Next generation clonal neoantigen targeting T cells, generated using the PELEUSTMbioinformatics platform and the VELOSTMmanufacturing method show superior reactivity and phenotypic characteristics than classical TIL products (2020) (0)
- Pervasive chromosomal instability and karyotype order in tumour evolution (2020) (0)
- SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay [version 2; peer review: 2 approved with reservations] (2021) (0)
- The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet? (2022) (0)
- Characterisation of the Fluorescence Associated with Human Serum Albumin Incubated with Glucose and Icodextrin-Based Peritoneal Dialysis Fluids (2005) (0)
- 87P Infliximab use in patients with checkpoint inhibitor toxicities: A tertiary centre experience (2022) (0)
- TCR sequencing: applications in immuno-oncology research (2023) (0)
- Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer (2023) (0)
- Contrasting the drivers of response to immunotherapy across solid tumour types: Results from analysis of > 1000 cases (2019) (0)
- Pharmacist and Nurse (PN) led melanoma immunotherapy clinic: Patient experience survey (2019) (0)
- Defining the mechanisms of response and resistance to anti-PD-1 therapy: An exploratory phase II study of pembrolizumab in advanced melanoma (ADAPTeM). (2016) (0)
- Whole genome error-corrected sequencing for sensitive circulating tumor DNA cancer monitoring (2022) (0)
- Author Correction: Resolving genetic heterogeneity in cancer (2019) (0)
- Resolving genetic heterogeneity in cancer (2019) (0)
- 221 Multi-region whole exome sequencing reveals monoclonal nature of inferior vena cava tumour thrombus extension in clear cell renal cell carcinoma (2016) (0)
- University of Birmingham Tracking the Evolution of Non-Small-Cell Lung Cancer (2017) (0)
- Isolated imbalance due to bilateral vestibular failure following immune checkpoint inhibitor administration (2021) (0)
- Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study (2021) (0)
- Optimisation of b-values for the accurate estimation of the apparent diffusion coefficient (ADC) in whole-body diffusion-weighted MRI in patients with metastatic melanoma (2022) (0)
- Why I pivoted from COVID-19 back to cancer research (2022) (0)
- Abstract 6794: SETD2 loss in renal cell carcinoma generates peptides from aberrantly translated retained introns (2023) (0)
- 179P Early proof of concept of safety and clinical activity of clonal neoantigen-reactive T cells (cNeT) (2022) (0)
- SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay [version 1; peer review: 2 approved with reservations] (2021) (0)
- Mechanism informs precision: In vivo determinants of response to anti-CTLA-4 antibodies. (2018) (0)
- Real-World EQ-5D-5L Utility Values In Patients With Melanoma Derived Using A Digital ‘Bring Your Own Device’ Platform (2018) (0)
- Standing on the shoulders of giants (2019) (0)
- 703MO An integrated study of spatial dynamics and genomic alterations in renal cell carcinoma evolution (2020) (0)
- SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay [version 1; peer review: awaiting peer review] (2021) (0)
- Pharmacist and nurse led melanoma immunotherapy clinic (2019) (0)
This paper list is powered by the following services:
Other Resources About Samra Turajlic
What Schools Are Affiliated With Samra Turajlic?
Samra Turajlic is affiliated with the following schools:
